KEGG   DRUG: TagraxofuspHelp
Entry
D11358                      Drug                                   

Name
Tagraxofusp (USAN/INN);
Tagraxofusp-erzs;
Elzonris (TN)
Product
Formula
C2553H4026N692O798S16
Exact mass
57659.1258
Mol weight
57694.4811
Sequence
MGADDVVDSS KSFVMENFSS YHGTKPGYVD SIQKGIQKPK SGTQGNYDDD WKGFYSTDNK
YDAAGYSVDN ENPLSGKAGG VVKVTYPGLT KVLALKVDNA ETIKKELGLS LTEPLMEQVG
TEEFIKRFGD GASRVVLSLP FAEGSSSVEY INNWEQAKAL SVELEINFET RGKRGQDAMY
EYMAQACAGN RVRRSVGSSL SCINLDWDVI RDKTKTKIES LKEHGPIKNK MSESPNKTVS
EEKAKQYLEE FHQTALEHPE LSELKTVTGT NPVFAGANYA AWAVNVAQVI DSETADNLEK
TTAALSILPG IGSVMGIADG AVHHNTEEIV AQSIALSSLM VAQAIPLVGE LVDIGFAAYN
FVESIINLFQ VVHNSYNRPA YSPGHKTRPH MAPMTQTTSL KTSWVNCSNM IDEIITHLKQ
PPLPLLDFNN LNGEDQDILM ENNLRRPNLE AFNRAVKSLQ NASAIESILK NLLPCLPLAT
AAPTRHPIHI KDGDWNEFRR KLTFYLKTLE NAQAQQTTLS LAIF
(Disulfide bridge: 187-202, 407-475)
  Type
Peptide
Remark
Product: D11358<US>
Efficacy
Antineoplastic, Immunotoxin
Comment
Diphteria toxin fusion protein with peptide and interleukin 3
Treatment of blastic plasmacytoid dendritic cell neoplasm (CD123-directed)
Target
IL3RA (CD123) [HSA:3563] [KO:K04737]
  Pathway
hsa04210  Apoptosis
hsa04640  Hematopoietic cell lineage
hsa05200  Pathways in cancer
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL3RA (CD123)
     D11358  Tagraxofusp (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11358
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11358
BRITE hierarchy
Other DBs
CAS: 2055491-00-2
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system